Company / Free Cash Flow
Arcus Biosciences, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$484.0M
FY2025
5-year range
-$484.0M / $108.0M
FY2021-FY2025
Trend
-175.0%
vs FY2024
Sector context
#186 of 194
Health Care
What the data says
Among 194 Health Care companies, Arcus Biosciences, Inc. is in the bottom 4% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$484M in FY2025 to $108M in FY2022.
Based on SEC 10-K filings.
-$484M in FY2025.
Declined from -$330M to -$484M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 194This company -$484.0M Sector average $470.6M
▼
-202.9% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 175.0% year-over-year.
- Ranks #186 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$484.0M | -175.0% |
| FY2024 | -$176.0M | +46.7% |
| FY2023 | -$330.0M | -405.6% |
| FY2022 | $108.0M | +138.3% |
| FY2021 | -$282.0M | -503.4% |
| FY2020 | -$46.7M | +38.0% |
| FY2019 | -$75.4M | -342.3% |
| FY2018 | -$17.0M | +44.3% |
| FY2017 | -$30.6M | -79.4% |
| FY2016 | -$17.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026